Literature DB >> 32611578

Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab.

Arnon P Kater1, Yanwen Jiang2, Brenda Chyla3, John F Seymour4.   

Abstract

Entities:  

Year:  2020        PMID: 32611578      PMCID: PMC7327665          DOI: 10.3324/haematol.2020.253849

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Authors:  Arnon P Kater; John F Seymour; Peter Hillmen; Barbara Eichhorst; Anton W Langerak; Carolyn Owen; Maria Verdugo; Jenny Wu; Elizabeth A Punnoose; Yanwen Jiang; Jue Wang; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Thomas J Kipps
Journal:  J Clin Oncol       Date:  2018-12-03       Impact factor: 44.544

2.  Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  John F Seymour; Thomas J Kipps; Barbara Eichhorst; Peter Hillmen; James D'Rozario; Sarit Assouline; Carolyn Owen; John Gerecitano; Tadeusz Robak; Javier De la Serna; Ulrich Jaeger; Guillaume Cartron; Marco Montillo; Rod Humerickhouse; Elizabeth A Punnoose; Yan Li; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Arnon P Kater
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

3.  BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Authors:  Daniela Asslaber; Nathalie Wacht; Michael Leisch; Yuan Qi; Nicole Maeding; Clemens Hufnagl; Bettina Jansko; Nadja Zaborsky; Andreas Villunger; Tanja N Hartmann; Richard Greil; Alexander Egle
Journal:  Clin Cancer Res       Date:  2018-11-28       Impact factor: 12.531

4.  Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.

Authors:  Eugen Tausch; Christof Schneider; Sandra Robrecht; Can Zhang; Anna Dolnik; Johannes Bloehdorn; Jasmin Bahlo; Othman Al-Sawaf; Matthias Ritgen; Anna-Maria Fink; Barbara Eichhorst; Karl-Anton Kreuzer; Maneesh Tandon; Kathryn Humphrey; Yanwen Jiang; William Schary; Lars Bullinger; Daniel Mertens; Michele Porro Lurà; Michael Kneba; Hartmut Döhner; Kirsten Fischer; Michael Hallek; Stephan Stilgenbauer
Journal:  Blood       Date:  2020-06-25       Impact factor: 22.113

5.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Authors:  Ferran Nadeu; Julio Delgado; Cristina Royo; Tycho Baumann; Tatjana Stankovic; Magda Pinyol; Pedro Jares; Alba Navarro; David Martín-García; Sílvia Beà; Itziar Salaverria; Ceri Oldreive; Marta Aymerich; Helena Suárez-Cisneros; Maria Rozman; Neus Villamor; Dolors Colomer; Armando López-Guillermo; Marcos González; Miguel Alcoceba; Maria José Terol; Enrique Colado; Xose S Puente; Carlos López-Otín; Anna Enjuanes; Elías Campo
Journal:  Blood       Date:  2016-02-02       Impact factor: 22.113

6.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

7.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

8.  Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Authors:  Fary Diop; Riccardo Moia; Chiara Favini; Elisa Spaccarotella; Lorenzo De Paoli; Alessio Bruscaggin; Valeria Spina; Lodovico Terzi-di-Bergamo; Francesca Arruga; Chiara Tarantelli; Clara Deambrogi; Silvia Rasi; Ramesh Adhinaveni; Andrea Patriarca; Simone Favini; Sruthi Sagiraju; Clive Jabangwe; Ahad A Kodipad; Denise Peroni; Francesca R Mauro; Ilaria Del Giudice; Francesco Forconi; Agostino Cortelezzi; Francesco Zaja; Riccardo Bomben; Francesca Maria Rossi; Carlo Visco; Annalisa Chiarenza; Gian Matteo Rigolin; Roberto Marasca; Marta Coscia; Omar Perbellini; Alessandra Tedeschi; Luca Laurenti; Marina Motta; David Donaldson; Phil Weir; Ken Mills; Patrick Thornton; Sarah Lawless; Francesco Bertoni; Giovanni Del Poeta; Antonio Cuneo; Antonia Follenzi; Valter Gattei; Renzo Luciano Boldorini; Mark Catherwood; Silvia Deaglio; Robin Foà; Gianluca Gaidano; Davide Rossi
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

  8 in total
  1 in total

Review 1.  Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.

Authors:  Mohammad Almasri; Marah Amer; Joseph Ghanej; Abdurraouf Mokhtar Mahmoud; Gianluca Gaidano; Riccardo Moia
Journal:  Life (Basel)       Date:  2022-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.